Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) requires balancing growth potential against value-oriented income. Both companies provide essential medicines, but their current financial paths differ significantly for investors in 2026. Amgen focuses on biologics and complex medicines for serious illnesses, while Bristol Myers Squibb emphasizes oncology and hematology treatments. They are being compared because both companies represent established players in the pharmaceutical landscape, each offering a different mix of growth and stability for investors seeking exposure to large-cap healthcare. Operating as a large biotech vs pharma player, Amgen discovers and develops innovative medicines across oncology and rare diseases. The company sells its products primarily through three major distributors, McKesson Corp. (NYSE:MCK) , Cencora (NYSE:COR) , and Cardinal Health (NYSE:CAH) . Customer concentration adds a layer of risk, as these wholesalers account for the majority of revenue. Continue reading